ecancer

Ramucirumab plus pembrolizumab improves OS in advanced NSCLC

Dr Roy Herbst - Yale Cancer Center, New Haven, USA

4 Jun 2022

Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100

Dr Grace Dy - Roswell Park Comprehensive Cancer Center, Buffalo, USA

10 May 2022

Nivolumab plus platinum-doublet chemo vs chemo as neoadjuvant treatment for resectable NSCLC

Prof Nicolas Girard - Institut Curie, Paris, France

10 May 2022

Recent advances in the treatment of patients with exon 20 insertion-positive NSCLC

Dr Alfredo Addeo, Prof Nicolas Girard and Prof Natasha Leighl

21 Apr 2022

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia

14 Apr 2022

Immune gene signatures for predicting response to neoadjuvant chemoimmunotherapy in NSCLC

Dr Marta Casarrubios - Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain

31 Mar 2022

Real-world increase in biomarker testing in lung cancer

Dr Virginia Calvo de Juan - Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain

30 Mar 2022

EGFR testing: Best practice for NSCLC patients with exon 20 insertions

Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari

30 Mar 2022

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

17 Feb 2022

Lung cancer in India

Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India

3 Feb 2022

OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more

Dr John Haanen, Dr Vivek Subbiah, Dr Christian Rolfo, Dr Jessica Hwang, Dr Nagla Karim, Dr Fumiko Chino, Dr Narjust Duma & Dr Nicole Kuderer

19 Jan 2022

OncoAlert Colloquium Day 2: Lung cancer and MASCC

Dr Stephen Liu, Dr Jack West, Dr Sanay Popat, Dr Jarushka Naidoo, Dr Percy Lee, Ms Jill Feldman, Ms Ivy Elkins, Dr Andrew Davies & Dr Joanne Bowen

19 Jan 2022

More from ecancer